



"

Attorney Docket P1085R4-1A

PATENT

CERTIFICATION UNDER 37 CFR 1.10

EM168882496US: Express Mail Number

Please type a plus sign (+) inside this box +

January 20, 1999: Date of Deposit

I hereby certify that this Non-provisional Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231

Yvonne E. Carter

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION Assistant Commissioner of Patents Washington, D.C. 20231

NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

Vanessa Hsei Iphigenia Koumenis Steven Leong Leonard Presta Zahra Shahrokh Gerardo Zapata

Title:

ANTIBODY FRAGMENT-POLYMER CONJUGATES AND HUMANIZED ANTI-IL-8 MONOCLONAL ANTIBODIES

1.	Tyne	οf	Ann	licatio	n
1.	IVDE	O.	ADD	ııcatıo	

- [] This application is for an original, non-provisional application.
- [X] This application is a non-provisional application filed under 37 CFR1.53(b), claiming priority under 35 USC119(e) to provisional application numbers 60/074,330 filed 22 January 1998; 60/094,013 filed 24 July 1998; 60/094,003 filed 24 July 1998; and 60/075,467 filed 20 February 1998, the contents of which are incorporated herein by reference.
- [] This is a [] continuation-in-part [] continuation [] divisional application claiming priority to application Serial Number___, filed ____, the entire disclosure of which is hereby incorporated by reference.
- 2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b) (Non-provisional)

299 pages of specification

__5__ pages of claims

3.	Declaration or Oath						
	(for new and CIP applications; also for Cont./Div. where inventor(s) are being added) X An unexecuted declaration of the inventor(s) [X] is enclosed [] will follow.						
	(for Cont./Div. where inventorship is the same or inventor(s) being deleted) A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).						
	(for Cont./Div. where inventor(s) being deleted) A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).						
4.	Assignment						
	(for new and CIP applications) X An Assignment of the invention to GENENTECH, INC. [] is enclosed with attached Recordation Form Cover Sheet [X] will follow.						
	(for cont./div.) The prior application is assigned of record to Genentech, Inc.						
5.	Amendments (for continuation and divisional applications)						
	Cancel in this application original claims of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)						
	A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)						
	Relate Back 35 U.S.C. 120 or 35 U.S.C. 119						
	Amend the specification by inserting before the first line the sentence:						
	This is a						
	non-provisional application continuation divisional continuation-in-part						

\$0.00

\$1,030.00

of co-pending	application:	S			
	incorporate 35 USC § Internation is (are) incorporate	ted herein by r 120 nal Application	eference and to filed on w	which application(s) hich designated the U	ch application(s) is(are) priority is claimed under .S., which application(s) tion(s) priority is claimed
	•	37 CFR 1.16) calculated as f	follows:		
		CLAIN	IS FOR FEE CA	LCULATION	
Number Filed		Number Extra		Rate	Basic Fee 37 CFR 1.16(a)
		*			\$760.00
Total Claims	35	- 20 =	15	X \$18.00	\$270.00
Independent Claims	1	- 3 =	0	X \$78.00	\$0.00

7. Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$1,030.00. A duplicate copy of this transmittal is enclosed.

+ \$260.00

Filing Fee Calculation

8. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. <u>A duplicate copy of this sheet is enclosed</u>.

9. Additional Papers Enclosed

- [] Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations
- [X] Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence.
- [] A new Power of Attorney or authorization of agent.

Multiple dependent claim(s), if any

[] Other:

10. Maintenance of Copendency of Prior Application (for continuation and divisional applications) [This item must be completed and the necessary papers filed in the prior application if the period set in the prior application has run] A petition, fee and/or response has been filed to extend the term in the pending prior application until A copy of the petition for extension of time in the prior application is attached. 11. Correspondence Address: Address all future communications to: _X_ GENENTECH, INC. Attn: Richard B. Love 1 DNA Way South San Francisco, CA 94080-4990

Respectfully submitted, GENENTECH, INC.

Date: January 20, 1999

Richard B. Love Reg. No. 34,659

1 DNA Way

So. San Francisco, CA 94080-4990

(650) 225-5530

Phone: (650) 225-5530 Fax: (650) 952-9881